ECSP15025570A - Formulaciones de pidotimod - Google Patents

Formulaciones de pidotimod

Info

Publication number
ECSP15025570A
ECSP15025570A ECIEPI201525570A ECPI201525570A ECSP15025570A EC SP15025570 A ECSP15025570 A EC SP15025570A EC IEPI201525570 A ECIEPI201525570 A EC IEPI201525570A EC PI201525570 A ECPI201525570 A EC PI201525570A EC SP15025570 A ECSP15025570 A EC SP15025570A
Authority
EC
Ecuador
Prior art keywords
pidotimod
formulations
acceptable salt
present
physiologically acceptable
Prior art date
Application number
ECIEPI201525570A
Other languages
English (en)
Inventor
Maurizio Caserini
Federico Mailland
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of ECSP15025570A publication Critical patent/ECSP15025570A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

La presente invención está dirigida a formulaciones de pidotimod, o una sal fisiológicamente aceptable del mismo, para tratar la dermatitis atópica. Para el tratamiento de la presente invención, pidotimod, o una sal fisiológicamente aceptable del mismo, preferiblemente se administra por vía tópica.
ECIEPI201525570A 2012-12-19 2015-06-16 Formulaciones de pidotimod ECSP15025570A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/076086 WO2014094839A1 (en) 2012-12-19 2012-12-19 Use of pidotimod to treat atopic dermatitis

Publications (1)

Publication Number Publication Date
ECSP15025570A true ECSP15025570A (es) 2016-01-29

Family

ID=47520053

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201525570A ECSP15025570A (es) 2012-12-19 2015-06-16 Formulaciones de pidotimod

Country Status (32)

Country Link
US (1) US20150352081A1 (es)
EP (1) EP2934520B1 (es)
JP (1) JP6058156B2 (es)
KR (1) KR20150095772A (es)
CN (1) CN104797254B (es)
AU (1) AU2012396941A1 (es)
BR (1) BR112015011394A2 (es)
CA (1) CA2889388A1 (es)
CY (1) CY1118633T1 (es)
DK (1) DK2934520T3 (es)
EA (1) EA201591184A1 (es)
EC (1) ECSP15025570A (es)
ES (1) ES2615748T3 (es)
HK (1) HK1210938A1 (es)
HR (1) HRP20161667T1 (es)
HU (1) HUE030408T2 (es)
IL (1) IL239292A0 (es)
LT (1) LT2934520T (es)
MA (1) MA38156B1 (es)
ME (1) ME02559B (es)
MX (1) MX2015008129A (es)
PH (1) PH12015501211A1 (es)
PL (1) PL2934520T3 (es)
PT (1) PT2934520T (es)
RS (1) RS55424B1 (es)
SG (1) SG11201503281QA (es)
SI (1) SI2934520T1 (es)
SM (1) SMT201700071B (es)
TN (1) TN2015000159A1 (es)
UY (1) UY35197A (es)
WO (1) WO2014094839A1 (es)
ZA (1) ZA201502983B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015036009A1 (en) * 2013-09-10 2015-03-19 Polichem S.A. Pidotimod for use in the treatment of inflammation-associated diseases
EP3754806A1 (en) 2019-06-19 2020-12-23 UTC Fire & Security EMEA BVBA Power supply device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) * 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
CA2467242A1 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
MA38156B1 (fr) 2017-03-31
EP2934520A1 (en) 2015-10-28
PL2934520T3 (pl) 2017-08-31
BR112015011394A2 (pt) 2017-07-11
RS55424B1 (sr) 2017-04-28
CY1118633T1 (el) 2017-07-12
CN104797254A (zh) 2015-07-22
DK2934520T3 (en) 2017-01-23
JP2016503042A (ja) 2016-02-01
WO2014094839A1 (en) 2014-06-26
MX2015008129A (es) 2015-09-23
HRP20161667T1 (hr) 2017-01-27
PH12015501211A1 (en) 2015-08-17
HUE030408T2 (en) 2017-05-29
HK1210938A1 (en) 2016-05-13
ES2615748T3 (es) 2017-06-08
KR20150095772A (ko) 2015-08-21
JP6058156B2 (ja) 2017-01-11
SG11201503281QA (en) 2015-07-30
PT2934520T (pt) 2017-02-16
UY35197A (es) 2014-06-30
CA2889388A1 (en) 2014-06-26
ZA201502983B (en) 2016-11-30
SMT201700071B (it) 2017-03-08
US20150352081A1 (en) 2015-12-10
AU2012396941A1 (en) 2015-05-28
EP2934520B1 (en) 2016-11-16
CN104797254B (zh) 2017-06-06
LT2934520T (lt) 2017-01-10
SI2934520T1 (sl) 2017-03-31
AU2012396941A2 (en) 2015-06-18
EA201591184A1 (ru) 2015-10-30
MA38156A1 (fr) 2016-08-31
ME02559B (me) 2017-02-20
TN2015000159A1 (en) 2016-10-03
IL239292A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
UY39646A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
GT201500051A (es) Inhibidores de glucosilceramida sintasa
PH12014501702A1 (en) Imidazopyrrolidinone compounds
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
PE20150887A1 (es) Compuestos de benceno sustituidos
ECSP12012160A (es) Compuesto heterociclico
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
CO7121334A2 (es) Formulaciones vesiculares
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
ECSP15025570A (es) Formulaciones de pidotimod
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
PH12015501210A1 (en) Use of pidotimod to treat psoriasis
PH12015502703A1 (en) Pharmaceutical compositions
PE20151159A1 (es) Uso de pidotimod para tratar la dermatitis atopica
AR118704A2 (es) Polipéptido del factor vii para tratar enfermedades